4.7 Article

Nrf2 Plays a Protective Role Against Intravascular Hemolysis-Mediated Acute Kidney Injury

Journal

FRONTIERS IN PHARMACOLOGY
Volume 10, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2019.00740

Keywords

intravascular hemolysis; hemoglobin; heme; Nrf2; oxidative stress; tubular injury; sulforaphane

Funding

  1. FIS/FEDER [CP14/00008, CP16/00014, CP16/00017, PI15/00448, PI16/00735, PI16/02057, PI17/00130, PI17/01495, PI17/01700]
  2. ISCIII-RETIC REDinREN [RD012/0021, RD016/0009]
  3. Spanish Ministry of Economy and Competitiveness [RYC-2017-22369]
  4. Fundacion Renal Inigo Alvarez de Toledo (FRIAT)
  5. Comunidad de Madrid [CIFRA2 B2017/BMD-3686, CIFRA2 B2017/BMD-3827]
  6. Fundacion La Caixa
  7. CaixaImpulse program [CI17-00048]
  8. Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM)

Ask authors/readers for more resources

Massive intravascular hemolysis is associated with acute kidney injury (AKI). Nuclear factor erythroid-2-related factor 2 (Nrf2) plays a central role in the defense against oxidative stress by activating the expression of antioxidant proteins. We investigated the role of Nrf2 in intravascular hemolysis and whether Nrf2 activation protected against hemoglobin (Hb)/heme-mediated renal damage in vivo and in vitro. We observed renal Nrf2 activation in human hemolysis and in an experimental model of intravascular hemolysis promoted by phenylhydrazine intraperitoneal injection. In wild-type mice, Hb/heme released from intravascular hemolysis promoted AKI, resulting in decreased renal function, enhanced expression of tubular injury markers (KIM-1 and NGAL), oxidative and endoplasmic reticulum stress (ER), and cell death. These features were more severe in Nrf2-deficient mice, which showed decreased expression of Nrf2-related antioxidant enzymes, including heme oxygenase 1 (HO-1) and ferritin. Nrf2 activation with sulforaphane protected against Hb toxicity in mice and cultured tubular epithelial cells, ameliorating renal function and kidney injury and reducing cell stress and death. Nrf2 genotype or sulforaphane treatment did not influence the severity of hemolysis. In conclusion, our study identifies Nrf2 as a key molecule involved in protection against renal damage associated with hemolysis and opens novel therapeutic approaches to prevent renal damage in patients with severe hemolytic crisis. These findings provide new insights into novel aspects of Hb-mediated renal toxicity and may have important therapeutic implications for intravascular hemolysis-related diseases.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Editorial Material Transplantation

Ageing meets kidney disease

Alberto Ortiz, Francesco Mattace-Raso, Maria Jose Soler, Denis Fouque

NEPHROLOGY DIALYSIS TRANSPLANTATION (2023)

Article Transplantation

Increasing numbers and improved overall survival of patients on kidney replacement therapy over the last decade in Europe: an ERA Registry study

Jilske A. Huijben, Anneke Kramer, Julia Kerschbaum, Johan de Meester, Frederic Collart, Olga Lucia Rodriguez Arevalo, Jaakko Helve, Mathilde Lassalle, Runolfur Palsson, Marc ten Dam, Anna Casula, Shona Methven, Alberto Ortiz, Pietro Manuel Ferraro, Marten Segelmark, Pablo Ucio Mingo, Mustafa Arici, Anna Varberg Reisaeter, Maria Stendahl, Vianda S. Stel, Kitty J. Jager

Summary: This study describes the trends in incidence, prevalence, and survival of patients on kidney replacement therapy (KRT) for end-stage kidney disease (ESKD) in Europe from 2008 to 2017. The incidence of KRT remained stable initially but increased slightly in recent years, primarily driven by an increase in older male patients. Diabetes mellitus was found to be a leading cause of kidney failure. The prevalence of KRT increased over the study period, and patient survival on KRT improved.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2023)

Editorial Material Transplantation

Chronic kidney disease as cardiovascular risk factor in routine clinical practice: a position statement by the Council of the European Renal Association

Alberto Ortiz, Christoph Wanner, Ron Gansevoort

Summary: The European Society of Cardiology 2021 guideline on cardiovascular disease prevention has significant implications for CV risk screening and kidney health. The guideline proposes specific strategies for individuals with established CVD, diabetes, hypercholesterolemia, or CKD. This includes the assessment of albuminuria as an entry-level step in CVD risk assessment, which could change current clinical practice. Further research is needed to determine the optimal method for CV risk assessment, including CKD assessment in the general population.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2023)

Article Transplantation

Trends in kidney transplantation rate across Europe: study from the ERA Registry

Rianne Boenink, Anneke Kramer, Rosalie E. Tuinhout, Emilie Savoye, Anders Asberg, Alma Idrizi, Julia Kerschbaum, Ieva Ziedina, Edita Ziginskiene, Emanuel Farrugia, Liliana Garneata, Elena Zakharova, Samira Bell, Miha Arnol, Marten Segelmark, Kyriakos Ioannou, Kristine Hommel, Mai Rosenberg-Ots, Evgueniy Vazelov, Jaakko Helve, Sandor Mihaly, Runolfur Palsson, Maurizio Nordio, Nikola Gjorgjievski, Aiko P. J. de Vries, Nurhan Seyahi, Winnie A. Magadi, Halima Resic, Aleh Kalachyk, Axel O. Rahmel, Ana A. Galvao, Radomir Naumovic, Torbjörn Lundgren, Mustafa Arici, Johan M. de Meester, Alberto Ortiz, Kitty J. Jager, Vianda S. Stel

Summary: This study aimed to analyze the trends in kidney transplantation rates in European countries. The results showed an overall increase in kidney transplantation rates from 2010 to 2018, including both deceased donor and living donor transplants, with substantial variations among different countries.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2023)

Editorial Material Transplantation

The new guidelines of the European Association of Urology on Urolithiasis: the urology-nephrology intersection

Giovanni Gambaro, Lazaros Tzelves, Andreas Skolarikos, Mehmet Kanbay, Alberto Ortiz, Mario Cozzolino

NEPHROLOGY DIALYSIS TRANSPLANTATION (2023)

Article Transplantation

Humoral response after the fourth dose of the SARS-CoV-2 vaccine in the CKD spectrum: a prespecified analysis of the SENCOVAC study

Borja Quiroga, Maria Jose Soler, Alberto Ortiz, Carlos Jesus Jarava Mantecon, Virginia Olinda Gomes Perez, Antoni Bordils, Jose Lacueva, Antonio Jose Marin Franco, Pablo Delgado Conde, Patricia Munoz Ramos, Carmen Calderon Gonzalez, Juan Manuel Cazorla Lopez, Jinny Sanchez-Rodriguez, Ana Sanchez Horrillo, Tania Raquel Monzon Vazquez, Alba Leyva, Jose Rojas, Ron T. Gansevoort, Patricia de Sequera

Summary: This study evaluated the humoral response and effectiveness of the fourth dose of COVID-19 vaccines in chronic kidney disease (CKD) patients. The fourth dose increased antibody levels in CKD patients undergoing hemodialysis and non-dialysis CKD patients, and seroconverted previously negative patients. However, CKD patients with lower pre-booster antibody titres or kidney transplant recipients derived the least benefit in terms of antibody levels.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2023)

Article Endocrinology & Metabolism

Extracellular vesicles of human diabetic retinopathy retinal tissue and urine of diabetic retinopathy patients are enriched for the junction plakoglo bin protein

Jason Mighty, Alfonso Rubio-Navarro, Cui Shi, Jing Zhou, Miguel Flores-Bellver, Soren Heissel, Onyekwere Onwumere, Linda Einbond, Rajendra Gharbaran, Daniel S. Casper, Alberto Benito-Martin, Stephen Redenti

Summary: Diabetic Retinopathy (DR) is a retinal disorder caused by diabetes. The lack of disease predictors makes the prognosis poor, leading to irreversible retinal damage and vision loss. Extracellular Vesicles (EVs) have the potential to be used as pre-symptomatic biomarkers for DR. EV proteins derived from urine may serve as noninvasive biomarkers.

FRONTIERS IN ENDOCRINOLOGY (2023)

Article Urology & Nephrology

Autosomal dominant polycystic kidney disease in young adults

Victor Martinez, Monica Furlano, Laia Sans, Lissett Pulido, Rebeca Garcia, Maria Vanessa Perez-Gomez, Jinny Sanchez-Rodriguez, Miquel Blasco, Cristina Castro-Alonso, Gema Fernandez-Fresnedo, Nicolas Roberto Robles, Maria Pau Valenzuela, Javier Naranjo, Nadia Martin, Melissa Pilco, Irene Agraz-Pamplona, Juan David Gonzalez-Rodriguez, Nayara Panizo, Gloria Fraga, Loreto Fernandez, Maria Teresa Lopez, Cecilia Dall'Anese, Alberto Ortiz, Roser Torra, Luis Marcas, Asuncion Rius, Patricia Tomas, Leonor Garcia, Enrique Luna, Maria Adoracion Martin, Pablo Inigo, Judith Martins, Fernanda Ramos, Rosa Garcia, Laura del Rio Garcia, Maria del Carmen Merino, M. Jose Fernandez-Reyes, Leire Madariaga, Cristina Canal, Ana Maria Martinez, Rocio Echarri, Hanane Bouarich, Antonio Cabezas

Summary: This study analyzed the clinical characteristics of autosomal dominant polycystic kidney disease (ADPKD) in young adults and found that they have a higher morbidity rate. This highlights the importance of comprehensive assessment for young individuals at risk of ADPKD, in order to enable early diagnosis and treatment of hypertension.

CLINICAL KIDNEY JOURNAL (2023)

Review Urology & Nephrology

Intravenous fluid therapy in accordance with kidney injury risk: when to prescribe what volume of which solution

Mehmet Kanbay, Sidar Copur, Berk Mizrak, Alberto Ortiz, Maria Jose Soler

Summary: Acute kidney injury (AKI) is a common condition in hospitalized patients, with risk factors including postoperative settings, baseline chronic kidney disease (CKD), and congestive heart failure. Intravenous (IV) fluid therapy is an essential component of AKI prevention and treatment. This review discusses the timing, fluid type, amount, and infusion rate of IV fluid therapy in hospitalized patients, as well as the potential adverse effects of different crystalloid and colloid solutions, specifically in patients with AKI, CKD, or heart failure, and their impact on the risk of hospital-acquired AKI.

CLINICAL KIDNEY JOURNAL (2023)

Review Biochemistry & Molecular Biology

Mitochondrial Dysfunction in the Cardio-Renal Axis

Nerea Mendez-Barbero, Jorge Oller, Ana B. Sanz, Adrian M. Ramos, Alberto Ortiz, Marta Ruiz-Ortega, Sandra Rayego-Mateos

Summary: Cardiovascular disease (CVD) often accompanies chronic kidney disease (CKD), and patients with both conditions have an increased risk of all-cause mortality ranging from 20% to 500%. Maintaining mitochondrial homeostasis appears to be a promising therapeutic strategy for the cardio-renal syndrome (CRS). This review explores the role of mitochondrial dysfunction in cardiovascular and renal diseases and how it may guide the development of novel therapeutic strategies for CRS.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Review Biochemistry & Molecular Biology

Novel Aspects of the Immune Response Involved in the Peritoneal Damage in Chronic Kidney Disease Patients under Dialysis

Flavia Trionfetti, Vanessa Marchant, Guadalupe. T. T. Gonzalez-Mateo, Edyta Kawka, Laura Marquez-Exposito, Alberto Ortiz, Manuel Lopez-Cabrera, Marta Ruiz-Ortega, Raffaele Strippoli

Summary: The global incidence of chronic kidney disease (CKD) is increasing, leading to a significant number of CKD patients developing end-stage renal disease (ESRD) and requiring kidney replacement therapies (KRT). Peritoneal dialysis (PD) is a convenient home therapy for KRT, but it can lead to damage of the peritoneal membrane (PM) due to the exposure to PD fluids containing high concentrations of glucose or other osmotic agents. This damage involves inflammation and fibrosis, which can be worsened by peritonitis episodes. In this article, we review the role of immune cells in PM damage during KRT and infections, as well as the anti-inflammatory properties of current clinical treatments for CKD patients in KRT and their potential effect on preserving PM integrity. Additionally, we discuss the implications of COVID-19 in CKD and KRT.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Cell Biology

A beta cell subset with enhanced insulin secretion and glucose metabolism is reduced in type 2 diabetes

Alfonso Rubio-Navarro, Nicolas Gomez-Banoy, Lisa Stoll, Friederike Dundar, Alex M. Mawla, Lunkun Ma, Eric Cortada, Paul Zumbo, Ang Li, Moritz Reiterer, Nathalia Montoya-Oviedo, Edwin A. Homan, Norihiro Imai, Ankit Gilani, Chengyang Liu, Ali Naji, Boris Yang, Angie Chi Nok Chong, David E. Cohen, Shuibing Chen, Jingli Cao, Geoffrey S. Pitt, Mark O. Huising, Doron Betel, James C. C. Lo

Summary: The pancreatic islets consist of hormone-producing cells that regulate systemic glucose balance. A subset of beta cells marked by high CD63 levels exhibits enhanced mitochondrial metabolism and insulin secretion. CD63-high beta cells are reduced in mouse models and humans with type 2 diabetes. Transplantation of CD63-high beta cell-derived pseudo-islets restores glucose homeostasis in diabetic mice.

NATURE CELL BIOLOGY (2023)

Editorial Material Pharmacology & Pharmacy

Editorial: NRF2 signaling pathway: New insights in the field of reno-cardiovascular health

Zeba Farooqui, Juan Antonio Moreno, Alfonso Rubio-Navarro

FRONTIERS IN PHARMACOLOGY (2023)

Article Biochemistry & Molecular Biology

Interaction of Fabry Disease and Diabetes Mellitus: Suboptimal Recruitment of Kidney Protective Factors

Maria D. Sanchez-Nino, Maria I. Ceballos, Sol Carriazo, Aranzazu Pintor-Chocano, Ana B. Sanz, Moin A. Saleem, Alberto Ortiz

Summary: The interaction between diabetes and Fabry disease may increase the severity of kidney damage by modulating the Gb3 synthesis pathway and downregulating kidney protective genes.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Oncology

Toll-like Receptor Signaling-deficient Cells Enhance Antitumor Activity of Cell-based Immunotherapy by Increasing Tumor Homing

Alvaro Morales-Molina, Miguel angel Rodriguez-Milla, Stefano Gambera, Teresa Cejalvo, Belen de Andres, Maria-Luisa Gaspar, Javier Garcia-Castro

Summary: Cancer immunotherapy aims to activate the immune system and deliver immunotherapeutic agents to tumors using carrier cells. This study found that using carrier cells with a low proinflammatory profile resulted in better tumor homing and improved antitumor responses, highlighting the importance of selecting appropriate cells for cell-based therapies in cancer treatment.

CANCER RESEARCH COMMUNICATIONS (2023)

No Data Available